Lifesci Capital Issues Positive Outlook for SLNO Earnings

Soleno Therapeutics, Inc. (NASDAQ:SLNO) – Investment analysts at Lifesci Capital raised their Q4 2025 earnings estimates for shares of Soleno Therapeutics in a report released on Monday, January 12th. Lifesci Capital analyst K. Dellorusso now anticipates that the company will earn $0.59 per share for the quarter, up from their prior forecast of $0.46. The consensus estimate for Soleno Therapeutics’ current full-year earnings is ($3.72) per share. Lifesci Capital also issued estimates for Soleno Therapeutics’ Q1 2026 earnings at $0.58 EPS, Q2 2026 earnings at $0.71 EPS, Q3 2026 earnings at $0.74 EPS, Q4 2026 earnings at $0.91 EPS and FY2026 earnings at $3.42 EPS.

Soleno Therapeutics (NASDAQ:SLNO) last announced its quarterly earnings results on Tuesday, November 4th. The company reported $0.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.08 by $0.39. The firm had revenue of $66.02 million during the quarter, compared to the consensus estimate of $47.46 million.

SLNO has been the subject of a number of other research reports. Robert W. Baird set a $107.00 price target on Soleno Therapeutics in a research report on Tuesday. Wells Fargo & Company reissued an “overweight” rating and set a $106.00 target price (down from $123.00) on shares of Soleno Therapeutics in a research note on Wednesday, November 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Soleno Therapeutics in a report on Wednesday, October 8th. The Goldman Sachs Group set a $125.00 price target on shares of Soleno Therapeutics and gave the company a “buy” rating in a report on Tuesday, October 7th. Finally, Wolfe Research set a $60.00 price objective on shares of Soleno Therapeutics in a research report on Monday. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Soleno Therapeutics presently has an average rating of “Buy” and a consensus target price of $109.23.

Soleno Therapeutics Stock Performance

Soleno Therapeutics stock opened at $41.95 on Thursday. The company has a current ratio of 16.08, a quick ratio of 15.88 and a debt-to-equity ratio of 0.10. The firm has a market cap of $2.25 billion, a P/E ratio of -22.80 and a beta of -3.12. Soleno Therapeutics has a 1-year low of $39.43 and a 1-year high of $90.32. The firm has a 50-day moving average of $47.68 and a 200-day moving average of $63.03.

Institutional Investors Weigh In On Soleno Therapeutics

Several hedge funds have recently made changes to their positions in SLNO. Raymond James Financial Inc. bought a new position in Soleno Therapeutics in the second quarter worth $25,000. Danske Bank A S purchased a new stake in shares of Soleno Therapeutics in the 3rd quarter worth about $27,000. Nisa Investment Advisors LLC grew its position in shares of Soleno Therapeutics by 287.8% in the 2nd quarter. Nisa Investment Advisors LLC now owns 539 shares of the company’s stock worth $45,000 after buying an additional 400 shares during the period. Aster Capital Management DIFC Ltd bought a new position in shares of Soleno Therapeutics in the 3rd quarter worth about $37,000. Finally, Quarry LP purchased a new position in Soleno Therapeutics during the 3rd quarter valued at about $47,000. 97.42% of the stock is currently owned by institutional investors.

Key Soleno Therapeutics News

Here are the key news stories impacting Soleno Therapeutics this week:

• Positive Sentiment: Lifesci Capital raised a string of quarterly and FY2026 EPS estimates (Q4 2025, Q1–Q4 2026 and FY2026 now $3.42 from $3.32), signaling a materially improved earnings outlook that could support re-rating if results and guidance align. Lifesci Capital estimates
• Positive Sentiment: Wells Fargo initiated/issued a buy on SLNO (coverage noted in a Globe and Mail press item), which can attract institutional buying and boost investor confidence. Soleno Therapeutics (SLNO) Receives a Buy from Wells Fargo
• Positive Sentiment: Zacks highlights a bullish “hammer” daily chart pattern and upward revisions in earnings estimates, arguing technical support could invite short-term reversals and buyer interest. Zacks technical/estimate note
• Neutral Sentiment: Market participation is muted: recent session volume was below the stock’s average and SLNO sits under its 50-day and 200-day moving averages, which can keep directional moves limited until clearer catalysts emerge. Market data
• Negative Sentiment: Some investors remain cautious — e.g., a Seeking Alpha piece explains reasons to stay on the sidelines (valuation, execution risk, or wait-for-data sentiment), which could depress demand despite upgrades and a buy rating. Seeking Alpha caution

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.